JP5230022B2 - 抗インターフェロンアルファモノクローナル抗体及び使用方法 - Google Patents

抗インターフェロンアルファモノクローナル抗体及び使用方法 Download PDF

Info

Publication number
JP5230022B2
JP5230022B2 JP2009524004A JP2009524004A JP5230022B2 JP 5230022 B2 JP5230022 B2 JP 5230022B2 JP 2009524004 A JP2009524004 A JP 2009524004A JP 2009524004 A JP2009524004 A JP 2009524004A JP 5230022 B2 JP5230022 B2 JP 5230022B2
Authority
JP
Japan
Prior art keywords
antibody
ifnα
aco
antibodies
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009524004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500380A5 (enrdf_load_stackoverflow
JP2010500380A (ja
Inventor
ジャック バンシュロー
キーリー プリリマン
ヴァージニア パスカル
アンナ カロリーナ パルッカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of JP2010500380A publication Critical patent/JP2010500380A/ja
Publication of JP2010500380A5 publication Critical patent/JP2010500380A5/ja
Application granted granted Critical
Publication of JP5230022B2 publication Critical patent/JP5230022B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009524004A 2006-08-09 2007-08-09 抗インターフェロンアルファモノクローナル抗体及び使用方法 Expired - Fee Related JP5230022B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83659906P 2006-08-09 2006-08-09
US60/836,599 2006-08-09
PCT/US2007/075616 WO2008021976A2 (en) 2006-08-09 2007-08-09 Anti-interferon alpha monoclonal antibodies and methods for use

Publications (3)

Publication Number Publication Date
JP2010500380A JP2010500380A (ja) 2010-01-07
JP2010500380A5 JP2010500380A5 (enrdf_load_stackoverflow) 2010-09-24
JP5230022B2 true JP5230022B2 (ja) 2013-07-10

Family

ID=39082973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524004A Expired - Fee Related JP5230022B2 (ja) 2006-08-09 2007-08-09 抗インターフェロンアルファモノクローナル抗体及び使用方法

Country Status (3)

Country Link
EP (1) EP2057190A4 (enrdf_load_stackoverflow)
JP (1) JP5230022B2 (enrdf_load_stackoverflow)
WO (1) WO2008021976A2 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5837730B2 (ja) 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
EP2687232A1 (en) * 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
AU2007327995B2 (en) * 2006-12-06 2013-10-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US8163885B2 (en) 2008-05-07 2012-04-24 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN106589122B (zh) * 2015-10-20 2020-10-27 中国人民解放军军事医学科学院生物工程研究所 人源抗人多亚型干扰素α抗体及其应用
EP3765069A1 (en) 2018-03-16 2021-01-20 Zoetis Services LLC Peptide vaccines against interleukin-31
MX2020009642A (es) 2018-03-16 2021-01-08 Zoetis Services Llc Anticuerpos monoclonales de interleucina-31 para uso veterinario.
RU2737466C1 (ru) * 2019-12-30 2020-11-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гуманизированное нейтрализующее антитело к интерферону-бета человека
CN112129952B (zh) * 2020-09-21 2023-06-06 普健生物（武汉）科技有限公司 一种检测人可溶性cd14的化学发光试剂盒
CN116284368B (zh) * 2022-06-15 2025-05-09 重庆艾生斯生物工程有限公司 抗人MxA抗体或其抗原结合部分

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法

Also Published As

Publication number Publication date
WO2008021976A3 (en) 2008-11-13
WO2008021976A2 (en) 2008-02-21
EP2057190A2 (en) 2009-05-13
JP2010500380A (ja) 2010-01-07
EP2057190A4 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
JP5837730B2 (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
JP5230022B2 (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
KR102048718B1 (ko) 항-cxcr4 항체 및 항체-약물 접합체
JP6289375B2 (ja) 抗ｉｌ−３６ｒ抗体
TWI487535B (zh) 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
EP3095797A1 (en) Anti dll3 antibodies and methods of use thereof
KR20090029231A (ko) 항―ｎｋｇ2ａ 항체 및 이들의 용도
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
TW201902925A (zh) 抗cd40抗體、其抗原結合片段及其醫藥用途
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
BR112019022702A2 (pt) gama de anticorpos anti-interferon e utilizações dos mesmos.
US7888481B2 (en) Anti-interferon alpha monoclonal antibodies and methods for use
JP2021530511A (ja) 抗ｐｄ−１抗体、投薬量、およびその使用
KR20220088428A (ko) 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
JP2024535124A (ja) 破傷風毒素に結合する抗体およびその使用
US20150166655A1 (en) Anti-interferon alpha monoclonal antibodies and methods of use
KR20220088438A (ko) 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
HK40003556B (en) Anti-gm-csf antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121030

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130318

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160329

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5230022

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees